USA – FDA Raises Questions on McKesson’s Ability to Detect Illegitimate Products

The US Food and Drug Administration (FDA) recently posted a Form 483 sent in July to the nation’s largest drug distributor, McKesson, and questioned the firm on how it detects illegitimate products.

The release of the Form 483 follows an investigation last year from the Washington Postand 60 Minutes highlighting McKesson’s failure to report suspicious orders involving millions of painkillers and opioids sent between facilities, some of which were reported to be fraudulent pharmacies. But government attorneys settled the case with McKesson, which paid a $150 million fine…